Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Total Non-Current Liabilities (2017 - 2025)

Catheter Precision (VTAK) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $7.0 million as the latest value for Q2 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 106.24% to $7.0 million in Q2 2025 year-over-year; TTM through Jun 2025 was $7.0 million, a 106.24% increase, with the full-year FY2023 number at $2.6 million, changed N/A from a year prior.
  • Total Non-Current Liabilities was $7.0 million for Q2 2025 at Catheter Precision, up from $6.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $11.7 million in Q2 2023 to a low of $2.4 million in Q1 2024.
  • A 3-year average of $6.1 million and a median of $5.3 million in 2024 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: tumbled 71.21% in 2024, then surged 167.05% in 2025.
  • Catheter Precision's Total Non-Current Liabilities stood at $2.6 million in 2023, then surged by 60.45% to $4.1 million in 2024, then soared by 69.12% to $7.0 million in 2025.
  • Per Business Quant, the three most recent readings for VTAK's Total Non-Current Liabilities are $7.0 million (Q2 2025), $6.5 million (Q1 2025), and $4.1 million (Q3 2024).